doi: 10.1016/j.indcrop.2015.04.059 14 AslamJ.MobinM.HudaA.AslamA.AslamR
However, we recognized in the CY 2025 OPPS/ASC proposed rule (89 FR 59201 through 59204) that there are rare instances in which cell and gene therapies appear on the same claim as a primary C-APC service and therefore, have their payment packaged with payment for the primary C-APC service
This stable, water-soluble peptide resists degradation in the digestive tract, allowing for oral administration in addition to parenteral routes such as intramuscular or subcutaneous injection
Compliance information: age and research-use acknowledgments, intended-use representations, fraud-prevention signals, and verification information reasonably requested for an order
Whats far more common is a career thats built incrementally, with many smaller successes building upon each other
Toxicol Lett 160:171177